AbbVie Reports Decrease in EPS for Full Year 2025

By Chris Stiles • Wednesday, February 04 11:44 • Permanent Link

AbbVie has reported its financial results for the full year and fourth quarter of 2025, showing a decrease in diluted EPS on a GAAP and adjusted basis. Full-year diluted EPS stood at $2.36 on a GAAP basis, a decrease of 1.3 percent, and $10.00 on an adjusted basis, a decrease of 1.2 percent. This includes an unfavorable impact of $2.76 per share related to 2025 acquired IPR&D and milestones expense.

The company delivered full-year net revenues of $61.160 billion, marking an increase of 8.6 percent on a reported basis and 8.5 percent on an operational basis. Notably, global net revenues from the immunology portfolio reached $30.406 billion, representing a 14.0 percent increase on a reported basis, or 13.9 percent on an operational basis. This was driven by strong performances from Skyrizi, Rinvoq, and Humira.

In the fourth quarter, AbbVie reported diluted EPS of $1.02 on a GAAP basis and adjusted diluted EPS of $2.71, which includes an unfavorable impact of $0.71 per share related to acquired IPR&D and milestones expense. Net revenues for the quarter were $16.618 billion, reflecting an increase of 10.0 percent on a reported basis and 9.5 percent on an operational basis.

Looking ahead, AbbVie provided adjusted diluted EPS guidance for 2026 in the range of $14.37 to $14.57, excluding any unfavorable impact related to acquired IPR&D and milestones expense.

The company has also made significant strides in its product development and expansion efforts, including submitting applications for new indications to regulatory authorities, receiving FDA approval for a new treatment, and engaging in strategic partnerships and acquisitions.

AbbVie's Chairman and CEO, Robert A. Michael, expressed confidence in the company's strong fundamentals and expected robust growth in 2026. This comes after the company's voluntary agreement with the Trump administration to enhance access and affordability for Americans while investing in U.S. pharmaceutical innovation.

The market has reacted to these announcements by moving the company's shares -1.11% to a price of $214.35. For the full picture, make sure to review AbbVie's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.